Exosome skincare starts with extracellular vesicles: tiny lipid-membrane bubbles that cells release to exchange proteins, lipids and RNA. Exosomes in cosmetics mostly come from plants, yeasts or bacteria; in the European Union, any human origin is banned. The evidence remains mostly preclinical.
Key takeaways
- The recommended scientific term is “extracellular vesicles” (EVs); “exosome” only designates a subtype whose origin must be demonstrated.
- Regulation (EC) no. 1223/2009 bans “cells, tissues or products of human origin” (Annex II, entry 416): exosomes from human stem cells are excluded from cosmetics sold in the EU.
- On an INCI list, plant vesicles are written “… Vesicles” or “… Extracellular Vesicles”, for example Rosa Damascena Callus Extracellular Vesicles.
- Most studies are in vitro or animal studies; the few human trials often combine exosomes with an aesthetic procedure.
- These vesicles are fragile: they require dedicated formulation and stability testing, and a supplier able to characterize them.
What is an exosome in skincare?
An exosome is an extracellular vesicle of roughly 50 to 150 nanometers, formed inside the cell and then released outside it, that carries proteins, lipids and nucleic acids. In its Canal Détox file of May 2025, Inserm points out that this size is about a thousand times smaller than the thickness of a hair (Inserm, 2025, in French).
An extracellular vesicle (EV) is a particle released by a cell, delimited by a lipid bilayer and unable to replicate on its own. This is the definition used by the international MISEV2023 guidelines (Journal of Extracellular Vesicles, 2024), which recommend the generic term “EV” rather than “exosome”, because the exact origin of a vesicle is hard to prove.
In practice, “exosome” is often a marketing word. For a brand, the useful question is what the ingredient really contains: source, particle size, concentration and purity.
Where do the exosomes used in cosmetics come from?
Exosomes in cosmetics come from four main families of sources, only one of which is excluded outright in Europe. Plant exosomes are isolated from juices, tissues or plant cell cultures (calluses); others come from yeast or bacterial fermentation, such as lactobacilli.
| Origin | Examples cited in the literature | Cosmetic status in the EU |
|---|---|---|
| Plant | Damask rose (callus culture), ginseng, green tea, aloe vera, centella | Allowed, subject to the product safety assessment |
| Microbial | Lactobacillus plantarum, yeasts | Allowed, with strict microbiological control |
| Animal | Salmon testes (a source cited by Inserm in the UK) | Not banned as such; origin and safety must be documented |
| Human | Stem cells from adipose tissue, bone marrow, umbilical cord | Banned (Annex II, entry 416) |
The review by Yang et al. (Extracellular Vesicles and Circulating Nucleic Acids, 2025) lists a dozen plant sources studied for skin, including ginseng, green tea, apple and aloe vera. To place these ingredients among the year’s other innovations, see our overview of trending cosmetic ingredients in 2026.
What does science really prove about exosomes in skincare?
To date, science does not show that an exosome cosmetic applied alone on healthy skin delivers a better result than a well-formulated conventional skincare product. Inserm states that there are no clinical trials on their aesthetic or cosmetic use and that no major finding proves an effect on wrinkles (Canal Détox, May 2025, in French).
A review published in the Anais Brasileiros de Dermatologia (Dal’Forno-Dini et al., 2024) notes that most studies remain preclinical: two systematic reviews from 2024 retained only nine small clinical studies in dermatology. Several combined exosomes with a laser or microneedling, which makes it impossible to isolate their own effect.
For plant exosomes, Yang et al. find only one trial registered on ClinicalTrials.gov, NCT06850935, which tests a centella vesicle formula in healthy volunteers. A 2026 review in the Journal of Clinical and Aesthetic Dermatology concludes that clinical data remain limited and that isolation methods vary from one study to another.
Another caveat: some authors declare ties to suppliers, and social media “before/after” photos often mix the active with an in-clinic procedure. This echoes what we found for PDRN, another fashionable biotech active.
Exosomes and EU regulation: what does Regulation 1223/2009 allow?
In the European Union, a cosmetic can contain plant, microbial or animal extracellular vesicles, but never vesicles of human origin. Annex II of Regulation (EC) no. 1223/2009 lists “cells, tissues or products of human origin” among the banned substances at entry 416.
The same text defines a cosmetic as a product intended for the “external parts of the human body” (Article 2): an injected product falls outside this framework. Claims must also comply with Article 20 and the common criteria of Regulation (EU) no. 655/2013: truthfulness, evidential support, honesty.
In practice, an exosome serum can claim that it moisturizes, smooths the look of skin or improves radiance, if tests support it. It cannot promise to “regenerate” skin or to treat a condition. Our guide on how cosmetic claims are regulated in Europe details these limits, and our article on changes in European cosmetic regulation in 2026 covers the other upcoming deadlines.
In Morocco
In Morocco, no cosmetic text specifically targets exosomes. Cosmetic products are notified to AMMPS, and a product that claims a therapeutic action falls under the medicinal product regime (Law 17-04). To export to Europe, the formula must in any case comply with Regulation 1223/2009. The steps are detailed in our AMMPS registration guide.
In the United States
The FDA does not publish a ban list equivalent to Annex II, but it reminds consumers that exosome products intended to treat a disease require its approval and that no exosome product is approved to date (FDA, consumer alert). A cosmetic intended for the United States must therefore stick to claims about appearance.
| Market | Human origin | Key takeaway |
|---|---|---|
| European Union | Banned (Annex II, entry 416) | Plant or microbial vesicles, claims about appearance only |
| Morocco | No specific text identified | AMMPS notification; any therapeutic claim shifts the product to the medicinal regime |
| United States | No equivalent cosmetic ban | No exosome product approved by the FDA; no treatment claims |
What is the INCI name for plant exosomes?
Plant exosomes almost never carry the word “exosomes” in their INCI name. The INCI nomenclature conventions of the Personal Care Products Council (2022) reserve this term for mammalian vesicles characterized by electron microscopy, flow cytometry or nanoparticle tracking analysis.
Plant vesicles, which are less well characterized, are named “Vesicles” after their source, for example Brassica Oleracea Italica (Broccoli) Vesicles. When they are released outside the cells, they become “Extracellular Vesicles”, such as Rosa Damascena Callus Extracellular Vesicles or Panax Ginseng Adventitious Root Extracellular Vesicles.
This has a practical consequence: if a supplier’s INCI list shows “Human … Exosomes”, the ingredient is of human origin and cannot go into a cosmetic sold in the EU.
Formulating with extracellular vesicles: what are the stability challenges?
Cosmetic extracellular vesicles are fragile structures, and their integrity depends as much on the process as on the formula. Yang et al. indicate that plant vesicles are unstable at room temperature and are generally stored at −80 °C; freeze-drying, with cryoprotectants such as sucrose or mannitol, is being studied as an alternative.
Surfactants pose another problem. Work published in Organic & Biomolecular Chemistry (Osteikoetxea et al., 2015) shows that SDS or Triton X-100 destroy extracellular vesicles at low concentrations. A foaming cleanser is therefore not the most logical vehicle for this active.
Here is the approach we follow to integrate this type of active:
- Read the technical data sheet: form (liquid, freeze-dried powder), storage conditions, recommended use level and stated compatibilities.
- Choose a gentle delivery system: aqueous serum, gel or light emulsion, limiting harsh surfactants.
- Add the active in the cold phase, at the end of manufacturing, under moderate stirring.
- Check the pH and the compatibility with the chosen preservative system.
- Run stability and packaging compatibility tests, then the preservation challenge test.
- Have the safety of the finished product assessed and gather evidence for each claim before any communication.
These checks follow the logic described in our article on the tests that guarantee the quality of a cosmetic.
PDRN vs exosomes: what are the differences?
PDRN and exosomes are often mentioned together, but they are two actives of a different nature. PDRN is fragmented, purified DNA, whereas an exosome is a whole vesicle that contains several families of molecules.
| Criterion | PDRN | Exosomes / extracellular vesicles |
|---|---|---|
| Nature | Purified DNA fragments | Lipid-membrane vesicles containing proteins, lipids, RNA |
| Common sources | Salmon or trout milt, plants | Plants, yeasts, bacteria (human banned in the EU) |
| Typical INCI name | Sodium DNA | … Vesicles / … Extracellular Vesicles |
| Maturity of evidence | A few randomized trials, mostly injectables | Mostly preclinical, rare human trials |
| Sensitive point in formulation | Molecular weight distribution | Vesicle integrity, surfactants, storage |
How do you evaluate an exosome supplier?
A serious exosome supplier must prove the origin, characterization and safety of its ingredient, not just display a trade name. Ask for at least:
- The exact origin: species, plant part or strain, and a written statement that no material of human origin is present.
- The INCI name and its consistency with the real nature of the ingredient.
- The characterization: particle size and concentration, and the method used (nanoparticle tracking, microscopy), with reference to MISEV2023.
- The certificate of analysis for each batch, with microbiological controls.
- The stability data of the ingredient and its transport conditions.
- The toxicology file the safety assessor needs, and any efficacy studies, with their protocol.
The manufacturer’s view
At Carmel Cosmetics Labs, which has supported 500+ brands in 35+ countries, we often see the same trap with trending actives: choosing the ingredient on the supplier’s promise, before checking its origin and what the brand can actually write on the label. Tranexamic acid in cosmetics illustrates this gap between studies and claims well.
Our advice is simple: start from the claim you want to be able to write, then work back to the active, the dosage and the tests needed. Our Agadir factory works to the GMP of ISO 22716 and formulates in compliance with Regulation 1223/2009, which frames these choices from the brief.
Frequently asked questions
Are human exosomes allowed in cosmetics in France?
No. France applies European Regulation 1223/2009, whose Annex II bans cells, tissues and products of human origin. A serum made from human stem cell exosomes therefore cannot be placed on the European market as a cosmetic. The “exosomes” sold in Europe are plant-based, microbial or, more rarely, animal.
Can you write “exosomes” on the packaging of a skincare product with plant vesicles?
The INCI name remains “Vesicles” or “Extracellular Vesicles”, but the term “exosomes” often appears in commercial messaging. Any mention must remain truthful within the meaning of Article 20 of the regulation: if the ingredient is not characterized as such, speaking of “plant vesicles” is safer.
Are exosomes suitable for a vegan brand?
Yes, if the ingredient is plant-derived or comes from fermentation, and if its carrier and process use no animal material. Ask the supplier for a written statement, because some “biotech” actives are produced on complex culture media.
What dosage of exosomes should you use in a serum?
There is no reference dosage. The review by Yang et al. (2025) stresses the absence of established concentration ranges for plant vesicles in cosmetics. The right level depends on the particle concentration of the ingredient, the supplier’s recommendation and the stability and tolerance tests run on the final formula.
Can an exosome cosmetic be used after an aesthetic procedure?
A cosmetic is applied to the skin, within the framework set by Regulation 1223/2009. Use on damaged skin or in combination with microneedling is a decision and responsibility for a healthcare professional, not something a cosmetic label can settle. For an aftercare range, the claim must stay cosmetic: soothing the feel of skin, moisturizing, protecting the look of skin.
Conclusion
Exosome skincare is a promising but still young active: plant or microbial vesicles, a precise INCI name, mostly preclinical evidence and a strict ban on human origin in the EU. Success in a formula depends as much on the supplier’s characterization as on stability and on cautious claims.
Considering a serum with extracellular vesicles? Our cosmetic formulation laboratory works with you on the active, the delivery system and defensible claims. Book a free consultation for your biotech formula with our team.